Unlocking Global Oncology Success: The Strategic Advantage of Australia & Asia for U.S. Biotechs

The oncology clinical trial landscape is evolving, and U.S. biotech companies are increasingly seeking innovative solutions to accelerate their drug development programs. This expert panel will explore how Australia, Taiwan, and South Korea provide a strategic advantage in conducting early, mid, and late-phase oncology trials, offering speed, cost efficiency, and global scalability.

Avance Clinical’s GlobalReady Pathway is a structured, regionally integrated clinical development framework that enables biotech sponsors to seamlessly transition from early-phase trials in Australia to mid-phase expansion in Asia and late-phase global execution, ensuring regulatory alignment, operational efficiency, and data integrity across all regions.